Sentinel lymph node biopsy in early breast carcinoma using fluorescein sodium and methylene blue dye: A validation study

Trop Doct. 2024 Oct;54(4):340-345. doi: 10.1177/00494755241264043. Epub 2024 Jul 23.

Abstract

The availability of radioisotopes for sentinel lymph node biopsy (SLNB) in breast carcinoma is limited in low- and middle-income countries and thus the need for other reliable tracers exists. We aimed to validate the effectiveness of fluorescein sodium (FS) together with methylene blue dye (MBD) for patients with node-negative early breast carcinoma in a prospective cross-sectional study. Patients underwent SLNB using FS and MBD followed by axillary dissection to validate results. Sentinel lymph node (SLN) identification rate and false negative rate were assessed for all three tracers/combinations (MBD, FS, and MBD + FS). We concluded that SLNB using a combination of FS and MBD has an acceptable rate of SLN identification but the addition of FS provided no additional benefit.

Keywords: Sentinel lymph node biopsy; early breast cancer; fluorescein sodium; methylene blue; node-negative breast cancer.

Publication types

  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Axilla
  • Breast Neoplasms* / pathology
  • Coloring Agents / administration & dosage
  • Cross-Sectional Studies
  • False Negative Reactions
  • Female
  • Fluorescein* / administration & dosage
  • Humans
  • Lymphatic Metastasis / diagnosis
  • Methylene Blue*
  • Middle Aged
  • Prospective Studies
  • Sentinel Lymph Node / pathology
  • Sentinel Lymph Node Biopsy* / methods

Substances

  • Methylene Blue
  • Fluorescein
  • Coloring Agents